Abstracts Archive - Page 144 of 2607 - ACR Meeting Abstracts

Abstract Number: 0014 • ACR Convergence 2025
NKX019, an allogeneic off-the-shelf CD19 targeting CAR-NK cell therapy, induces deep CD19+ B cell depletion in hematological malignancy and models of autoimmune disease
Mira Tohmé, Meriam Vejiga, Wendy Yu, Emily Kang, Katharine Yu, Jessica Sood, Ivan Chan, Kyle Hansen, David Shook and Phung Gip, Nkarta, South San Francisco, CA
Background/Purpose: Autologous CAR T-cell therapies have remarkable clinical activity in autoimmune disease (AD) via B-cell targeting, with many patients achieving durable, drug-free remission. However, safety…
Abstract Number: 0273 • ACR Convergence 2025
Effector CD8+ T cells and PD-1hi CXCL13hi CD4+ T cells contribute to recurrent immune checkpoint inhibitor mediated inflammatory arthritis
Synat Keam¹, Yuanteng Li², Yanshuo Chu¹, Jean Tayar³, Huifang Lu⁴, Michael Wu⁵, Sandeep Agarwal⁶, Nitin Jain⁷, Pavlos Msaouel¹, Adi Diab², Cara Haymaker¹, Linghua Wang¹, Roza Nurieva⁸ and Sang Kim⁹, ¹The University of Texas MD Anderson Cancer Center, houston, ²MD Anderson Cancer Center, Houston, TX, ³The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁴UT MD Anderson Cancer Center, Houston, TX, ⁵Baylor College of Medicine, Houston, ⁶Baylor College of Medicine, Houston, TX, ⁷The Universty of Texas MD Anderson Cancer Center, Houston, ⁸University of Texas MD Anderson, Houston, TX, ⁹Yale University, Branford, CT
Background/Purpose: Immune checkpoint inhibitor (ICI) therapy is associated with life- and/or organ-threatening immune-related adverse events, including inflammatory arthritis (ICI-IA). However, the mechanisms behind ICI-IA, especially…
Abstract Number: 0274 • ACR Convergence 2025
Transplant-free survival in patients with systemic autoimmune rheumatic diseases and progressive pulmonary fibrosis in the ILD-PRO Registry
Sonali Bracken¹, Aparna Swaminathan², Jeremy M Weber³, Megan L Neely⁴, Scott Palmer⁴, Erin Wilfong⁵, Ann Chauffe⁶ and Elizabeth Volkmann⁷, ¹Duke University Medical Center, Durham, NC, USA, Apex, NC, ²Duke University Medical Center and Duke Clinical Research Institute, Durham, NC, USA, Durham, NC, ³Duke Clinical Research Institute, Durham, NC, USA, Durham, ⁴Duke University Medical Center and Duke Clinical Research Institute, Durham, NC, USA, Durham, ⁵Vanderbilt University Medical Center, Nashville, TN, USA, Nashville, TN, ⁶Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Newberry, FL, ⁷Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA
Background/Purpose: Progressive pulmonary fibrosis (PPF) is known to be associated with high mortality, but there are few data on the course of PPF in patients…
Abstract Number: 0261 • ACR Convergence 2025
Randomized Confirmatory Basket Trial: Performance Evaluation of a Simulated Application Example in Rare Disease Using Real World Data
Daphne Guinn¹, Linchen He², Yuru Ren¹, Valeriy Korostyshevskiy¹ and Robert Beckman¹, ¹Georgetown University, Washington, ²Novartis, East Hanover
Background/Purpose: Basket trials group together participants who share a common biomarker or disease pathway across several diseases or phenotypes in a single clinical study. Such…
Abstract Number: 0279 • ACR Convergence 2025
Assessment of Baseline IgG4-RD Disease Characteristics and Impact Upon Safety and Efficacy of Inebilizumab: Results from the MITIGATE Study
Yoshiya Tanaka¹, Emma Culver², Arezou Khosroshahi³, Wen Zhang⁴, Kazuichi Okazaki⁵, Matthias Lohr⁶, nicolas schleinitz⁷, Xinxin Dong⁸, melissa rosen⁹, Sue Cheng⁸, Daniel Cimbora⁸ and John Stone¹⁰, ¹University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²John Radcliffe Hospital; University of Oxford, Oxford, United Kingdom, ³Emory University, Atlanta, GA, ⁴Peking Union Medical College Hospital, Dong Cheng Qu, China (People's Republic), ⁵Kansai Medical University Kori Hospital, Osaka, Japan, ⁶Karolinska Institutet, Stockholm, Sweden, ⁷Aix Marseille university, AP-HM, Marseille, France, ⁸Amgen, Thousand Oaks, CA, ⁹Amgen Inc., Thousand Oaks, CA, ¹⁰Massachusetts General Hospital , Harvard Medical School, Concord, MA
Background/Purpose: IgG4-related disease (IgG4-RD) is a progressive, systemic, fibroinflammatory disease characterized by unpredictable and recurring flares, leading to organ damage and decreased quality of life.…
Abstract Number: 0302 • ACR Convergence 2025
Urine Kynurenine Pathway Biomarkers Correlate with Disease Activity and Damage Core Set Measures in JDM
Shannon O'Connor¹, Hermine Brunner¹, Josh Gunn², Payam Farhadi³, Carley Phillips⁴, Lisa Rider⁵, Alexei Grom¹ and Sheila Angeles-Han⁶, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Ethos R&D, Newport, KY, ³National Institutes of Health/National Institute of Environmental Health Sciences, Bethesda, MD, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, ⁵National Institute of Environmental Health Sciences/National Institutes of Health, Environmental Autoimmunity Group, Bethesda, MD, ⁶Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Juvenile dermatomyositis (JDM) is an autoimmune vasculopathy affecting muscle, skin, and vasculature. Core set measures (CSM) assess disease activity and damage, and guide treatment.…
Abstract Number: 0283 • ACR Convergence 2025
The Performance of Rule-Based Algorithms to Identify Patients With Idiopathic Inflammatory Myopathies in Electronic Health Records
Ana Valle¹, Amy Vo², Rochelle Castillo¹, Yumeko Kawano³, Leah Santacroce³, Daniel Solomon⁴, Katherine Liao³ and Candace Feldman³, ¹Brigham and Women's Hospital, Brookline, MA, ²Harvard Medical School, Boston, ³Brigham and Women's Hospital, Boston, MA, ⁴Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Idiopathic inflammatory myopathies (IIM; including dermatomyositis, polymyositis, and inclusion body myositis) are heterogenous systemic inflammatory conditions that cause significant disability and morbidity. The study…
Abstract Number: 0035 • ACR Convergence 2025
Clinical and Transcriptomic Heterogeneity in Patients With RA: A Multi-Centric International Study of Anti-TNF Response
Maryna Borshchivska¹, Thibault Helleputte¹, Laurent Meric de Bellefon², Silvana di Romana³, Elsa Vieira-Sousa⁴, Vasco Romão⁴, João Eurico Fonseca⁵, Alla Ishchenko⁶, Patrick Verschueren⁶, Ruth Wittoek⁷, Peggy jacques⁷, Dirk Elewaut⁸, Bernard Lauwerys⁹ and Patrick Durez¹⁰, ¹DNAlytics, Louvain-la-Neuve, Belgium, ²Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatologie, Brussels, Belgium, ³Department of Rheumatology, Saint Pierre University Hospital, Brussels, Belgium, ⁴Faculdade Medicina, Universidade de Lisboa, ULS Santa Maria, Centro Académico Medicina de Lisboa, Lisboa, Portugal, ⁵Faculdade Medicina, Universidade de Lisboa, ULS Santa Maria, Centro Académico Medicina de Lisboa, Lisboa, Lisboa, Portugal, ⁶Rheumatology, University Hospital Leuven and Skeletal Biology and Engineering Research Centre, KU Leuven, Leuven, Belgium, ⁷VIB Center for Inflammation Research, Ghent University and Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁸VIB Center for Inflammation Research, and Ghent University Hospital, Department of Rheumatology, Ghent, Belgium, ⁹Systemic and Inflammatory Rheumatic Diseases Section, Institute of Experimental and Clinical Research (IREC), UCLouvain, Brussels, Belgium, ¹⁰Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatologie, Brussels, Brussels Hoofdstedelijk Gewest, Belgium

Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease that can lead to joint damage and disability. Although methotrexate is the standard first-line treatment, about…
Abstract Number: 0281 • ACR Convergence 2025
Anti-IL-6 Autoantibodies and IL-6 Signalling in Idiopathic Inflammatory Myopathies
Anja Srpcic¹, Manca Ogric¹, Sasa Cucnik¹, Sergej Pirkmajer², Katja Lakota¹ and Katja Perdan Pirkmajer¹, ¹University Medical Centre Ljubljana, Ljubljana, Slovenia, ²Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of systemic autoinflammatory diseases that affect muscle tissue, often leading to muscle atrophy, weakness and myalgia.…
Abstract Number: 0271 • ACR Convergence 2025
Clinical Presentation of Igg4-Related Disease. Multicenter Study and Literature Review
Rafael Gálvez Sánchez¹, Fernando Lopez Gutierrez², Javier Loricera³, Pablo Martínez Calabuig⁴, Jorge Juan Fragío Gil⁵, Roxana González Mazario⁶, Cristina Hormigos Martin⁷, DALIFER FREITES⁸, Maria Rodriguez Laguna⁹, Patricia Moya Albarado¹⁰, Marta López i Gómez¹¹, Hector Corominas¹², Maite Silva-Diaz¹³, GUILLERMO GONZALEZ ARRIBAS¹⁴, Angel Garcia-Aparicio¹⁵, Judit Font-Urgelles¹⁶, Ivette Casafont-Solé¹⁶, elisabeth Castañeda¹⁷, Carolina Merino¹⁸, Raquel Zas¹⁹, Juan Molina-Collada²⁰, Sergio Rodríguez Montero²¹, Rafael B. Melero-González²², Eva Galíndez Agirregoikoa²³, Andrea Hernández²⁴, Lucia Pantoja²⁵, Ignacio Braña²⁶, Vega Jovaní²⁷, Elia Valls-Pascual²⁸, Natalia Mena Vázquez²⁹, Adela Gallego³⁰, Noelia Cabaleiro Raña³¹, Raul Veroz³², Mariano Andrés Collado³³, Santos Castañeda³⁴ and Ricardo Blanco³⁵, ¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, Immunopathology Group -IDIVAL, Reumatología, Santander, Santander, Spain, ³Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ⁴Hospital General Universitario de Valencia, Spain/ Uversidad Catolica de Valencia San Vicente Martir, Valencia, Spain, Ontinyent, Spain, ⁵Hospital General Universitario, Valencia, Spain, ⁶Hospital General de Valencia, Valencia, Spain, ⁷Hospital Clínico San Carlos, Madrid, Spain, ⁸Rheumatology Service, San Carlos Clinical Hospital, Madrid, Madrid, Spain, ⁹Hospital Clinico San Carlos, Madrid, Spain, ¹⁰Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ¹¹Hospital Universitario de Araba, Vitoria, Pais Vasco, Spain, ¹²Hospital de Sant Pau, Barcelona, Spain, ¹³Complexo Hospitalario Universitario A Coruña, A Coruña, Galicia, Spain, ¹⁴Facultativo especialista, PALMA DE MALLORCA, Galicia, Spain, ¹⁵Hospital Universitario de Toledo, Toledo, Spain, ¹⁶Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹⁷Hospital Universitario Infanta Sofía, Madrid, Madrid, Spain, ¹⁸Rheumatology department. Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda (Madrid), Madrid, Spain, ¹⁹Hospital Universitario Doce de Octubre, Madrid, Spain, ²⁰Department of Rheumatology, Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain, Madrid, Spain, ²¹Hospital Universitario de Valme, Sevilla, Andalucia, Spain, ²²COMPLEXO HOSPITALARIO UNIVERSITARIO DE OURENSE, O Carballino, Spain, ²³BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ²⁴Hospital Universitario de Gran Canaria Dr Negrin, Palmas de Gran Canaria, Canarias, Spain, ²⁵Complejo Hospitalario Segovia, Segovia, Spain, ²⁶Hospital Universitario Central de Asturias, Oviedo, Spain, ²⁷Hospital General Universitario de Alicante, Reumatología, Alicante, Alicante, Comunidad Valenciana, Spain, ²⁸Hospital General de Valencia, Valencia, Comunidad Valenciana, Spain, ²⁹Hospital Regional Universitario de Malaga, Malaga, Spain, Málaga, Spain, ³⁰Complejo Hospitalario don Benito Villanueva, Badajoz, Spain, ³¹Hospital Universitario Montecelo, Rheumatology, Pontevedra, Galicia, Spain, ³²Hospital de Merida, Merida, Extremadura, Spain, ³³Hospital General Universitario de Alicante, Madrid, Comunidad Valenciana, Spain, ³⁴Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ³⁵Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: IgG4-related disease (IgG4-RD) is a systemic fibroinflammatory entity that can involve almost every organ, with characteristic histological features. Its pathogenesis remains poorly understood, clinical…
Abstract Number: 0304 • ACR Convergence 2025
Concordance for myositis-specific autoantibody detection between commercial enzyme-linked immunosorbent assay and line blot assay: a multi-center study across the Asia-Pacific region
Takahisa Gono¹, Vidya Limaye², Latika Gupta³, Vikas Agarwal⁴, Ho So⁵, JASMIN RAJA⁶, Warren Weng Seng Fong⁷, Suparaporn Wangkaew⁸, Andrea Low⁹, Akihiro Murakami¹⁰, Kimiko Hasegawa¹⁰, Takuya Isayama¹¹ and Masataka Kuwana¹, ¹Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ²Royal Adelaide Hospital, Adelaide, South Australia, Australia, ³School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham; Royal Wolverhampton NHS Trust; Centre for Musculoskeletal Research, School of Biological Sciences, The University of Manchester, Manchester; Francis Crick Institute, London, Birmingham, UK, United Kingdom, ⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ⁵Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁶University Malaya, Subang Jaya, Malaysia, ⁷Singapore General Hospital, Singapore, ⁸Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand, ⁹Singapore General Hospital, Singapore, Singapore, ¹⁰Medical & Biological Laboratories co., ltd., Tokyo, ¹¹Medical & Biological Laboratories co., ltd., Tokyo, Japan
Background/Purpose: RNA/protein immunoprecipitation (IP) assays remain the “gold standard” for myositis-specific autoantibody (MSA) detection. However, the requirements for large-scale cell culture and radioisotopes limit its…
Abstract Number: 0231 • ACR Convergence 2025
A Quality Improvement Project to Explore the Implications of the 2020 ACR Gout Guideline Recommendations for HLA-B5801 Testing
Sarah Anstett¹, Brian Coburn², Carlos Garcia-Gonzalez³, Max Krall¹, Akash Gupta⁴, Riya Madan⁵, Stephanie Lee⁶, Tania Aguila¹, Adam Mayer⁷, Elise Breed², Preethi Thomas⁸, Nora Sandorfi¹, Anupama Shahane¹ and Rachel Dayno¹, ¹University of Pennsylvania, Philadelphia, PA, ²Hospital of the University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, ⁴Hospital of University of Pennsylvania, Philadelphia, PA, ⁵University of Pennsylvania Medical Center, Philadelphia, PA, ⁶University of Pennsylvania and Children's Hospital of Philadelphia, Philadelphia, PA, ⁷University of Pennsylvania/Children's Hospital of Philadelphia, Philadelphia, PA, ⁸UNIVERSITY OF PENNSYLVANIA, Conshohocken, PA
Background/Purpose: The presence of the HLA-B5801 allele increases the risk of life-threatening allopurinol hypersensitivity syndrome (AHS). The 2020 ACR gout management guidelines conditionally recommend HLA-B5801…
Abstract Number: 0192 • ACR Convergence 2025
Digital Empowerment on Hold: Adoption Gaps in Prescribable Digital Health Applications – A National Cross-Sectional Study from Germany
Phillip Kremer¹, Daniel Fink², Harriet Morf³, Hannah Labinsky⁴, Karolina Gente⁵, Peer Aries⁶, Martin Krusche¹, Sebastian Kuhn⁷, Axel Hueber⁸ and Johannes Knitza⁹, ¹Division of Rheumatology and Systemic Inflammatory Diseases, III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, ²Rheumazentrum Mittelhessen, Bad Endbach, Germany, ³Department of Medicine ³ - Rheumatology & Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ⁴University Hospital of Wuerzburg, Würzburg, Germany, ⁵Department of Internal Medicine V - Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Baden-Wurttemberg, Germany, ⁶Department of Rheumatology, Immunologikum, Hamburg, Germany, ⁷Institute for Digital Medicine, University Hospital of Giessen and Marburg, Philipps University Marburg, Marburg, Germany, ⁸Klinikum Nuernberg, Nuernberg, Germany, ⁹Institute for Digital Medicine, University Hospital Gießen-Marburg, Philipps University, Marburg, Germany
Background/Purpose: Rheumatic and musculoskeletal diseases (RMDs) are chronic conditions that require complex, multidisciplinary care. Since 2020, digital health applications (DiGAs) have been available for prescription…
Abstract Number: 0293 • ACR Convergence 2025
Presence of Anti-cN-1A (Mup44, NT5c1A) IgG is Specific for Sporadic Inclusion Body Myositis
Jackie Weiss¹, Miriam Mende², EunByul Cho³, Guo Shen³, Dmitry Karayev³, Allan L. Metzger³, Robert I. Morris³, Sabine L. Kramp², Cornelia Dähnrich² and Wolfgang Schlumberger², ¹EUROIMMUN US, Mountain Lakes, NJ, ²Institute for Experimental Immunology, affiliated with EUROIMMUN Medizinische Labordiagnostika AG, Lübeck, Germany, ³RDL Reference Laboratory Inc., Los Angeles, CA
Background/Purpose: Sporadic inclusion body myositis (sIBM) is an autoimmune disease manifesting with muscle degeneration, inflammatory infiltrates and inclusion vacuoles. Diagnosis of sIBM is hampered by…
Abstract Number: 0209 • ACR Convergence 2025
A Retrospective Safety Analysis based on Platelets in Arthrocentesis and Joint injections in Cancer Patients
Yuanteng Li¹, Cheuk Leung², Heather Lin², Angeles Lopez-Olivio³ and Jean Tayar³, ¹MD Anderson Cancer Center, Houston, TX, ²MD Anderson Cancer Center, Houston, ³The University of Texas, MD Anderson Cancer Center, Houston, TX
Background/Purpose: Arthrocentesis and joint injections are commonly performed to diagnose and to treat rheumatic conditions such as crystal-induced arthritis, septic arthritis, and inflammatory arthritis. While…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].